75.962 Labeling of Cannabis Products with the Letters MD and DO The Medical Society of the State of New York seeks enforcement of the current legislation that prevents the use of the letters MD or DO and the words physician or doctor on the labeling or advertising of cannabis products. (HOD 2025-163)
75.963 Warning labels on OTC sleep aids Our Medical Society of the State of New York advocate for legislation or mandate from the appropriate regulators that over the counter (OTC) sleep medications containing antihistamines carry a warning label for adverse effects including, but not limited to dizziness, risk of falling, and, with long term use,
75.964 340B Regulations The Medical Society of the State New York supports greater transparency of health care entities participating in the 340B Drug Discount Program including a publicly available report of covered entities’ 340B savings and the percentage of 340B savings used directly to care for underinsured patients and lower-income patients; and that the Medical
75.970 Patient Medication Safety The Medical Society of the State of New York will continue to advocate together with the American Medical Association in support of efforts to ensure that the FDA has all the resources necessary to perform necessary inspection and testing of the manufacturing of medications, as well as preventing against drug shortages.
75.969 Medicare Coverage of OTC Nicotine Replacement Therapy MSSNY will advocate for OTC nicotine replacement therapies, excluding vaping products, to be carved out from the non-coverage by Medicare of OTC products and be specifically covered when prescribed by physicians who care for patients with Medicare, Medicare Part D, or Medicare Part C coverage. MSSNY will
75.968 Medication Not Approved by FDA For Use in Humans The Medical Society of the State of New York (MSSNY) will advocate for New York State legislation stating that insurance companies and other related entities must never be required to pay for substances not approved by FDA for use in humans. MSSNY will urge the
75.967 Appropriate Warning Labels and Signs for Vape and Marijuana MSSNY will advocate for clear and legible warnings on products containing THC and/or nicotine regardless of the vehicle in which they are contained. MSSNY will also advocate for clear, legible warning signs to be posted in businesses that sell products containing THC and/or nicotine. (HOD
75.966 Medical Use of Psilocybin and 3, 4-Methylenedioxymethamphetamine (MDMA) MSSNY awaits FDA evaluation of psilocybin and MDMA clinical trials completed and underway so that scientific data informs judgments about risks and benefits of treatment. MSSNY will advocate that New York State wait for the FDA to approve psilocybin and MDMA as safe medications with guidance
75.965 Rapid Response to Medication and Device Shortages The Medical Society of the State of New York will provide information on the MSSNY website on how to report drug shortages to the Food and Drug Administration. MSSNY will work with the American Medical Association on its efforts to help mitigate drug Shortages, and these efforts
75.999 Amphetamines: SUNSET HOD 2013
